An effective universal vaccine ideally providing broad protection against all influenza A virus (IAV) subtypes with pandemic or zoonotic potential circulating in animals, as well as against antigenically variable seasonal strains, remains an urgent public health need. Read More
Protein functional sites usually include a small number of residues that are crucial for binding or catalytic functions. One approach for the design of proteins with new functions consists of designing an amino acid sequence that folds up to a 3D structure containing the site, given a functional site description from any source. Read More
Investigators from Emory University and affiliated organizations presented preclinical data for the IAP inhibitor AZD-5582 (AstraZeneca), which has previously demonstrated the ability to systemically reverse latency in animal models of HIV. Read More
Jinan University and Guangzhou Lixin Pharmaceuticals have presented new 2-aminopyrimidine compounds acting as tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of cancer and inflammation. Read More
Rhizen Pharmaceuticals and Incozen Therapeutics have synthesized new cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, Alzheimer's disease, pulmonary fibrosis, inflammatory disorders, psoriasis and rheumatoid arthritis, among other disorders. Read More
Design Therapeutics has discovered conjugates consisting of a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to a protein-binding moiety through an oligomeric backbone linker reported to be useful for the treatment of Friedreich ataxia. Read More
The University of Texas System has described new nimbolide derivatives reported to be useful for the treatment of cancer, especially poly [ADP-ribose] polymerase (PARP)-resistant cancer. Read More
Researchers at Beijing Institute of Pharmacology and Toxicology have reported the discovery of novel CRBN-recruiting epidermal growth factor receptor (EGFR) degraders as candidates for the treatment of non-small cell lung cancer (NSCLC). Synthesis and optimization of a series of CRBN-recruiting EGFR degraders led to the identification of compounds [I] and [II] as the lead candidates. Read More
Caris Life Sciences and Xencor have entered into a multi-year strategic option and license agreement to research, develop and commercialize XmAb bispecific antibodies directed against novel targets for the treatment of patients with cancer. Read More
Vaxxinity has selected VXX-401 to pursue as its anti-proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) vaccine candidate to treat hypercholesterolemia, and reported data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in nonhuman primates. Read More
A study published in the July 28, 2022, online edition of Cell Chemical Biology shows that perturbation of thiamine (vitamin B1) metabolism inhibits Pseudomonas aeruginosa growth and sensitizes the bacterium to multiple antibiotics, opening up new avenues for much-needed combination therapies to treat pseudomonal infections. Read More
At the Alzheimer's Association International Conference, Dong-A ST scientists described preclinical research on a new tau-targeted agent, DA-7503. Read More
Xenetic Biosciences and VolitionRx have entered into a research and development collaboration to develop neutrophil extracellular traps (NETs)-targeted, adoptive cell therapies for the treatment of cancer. Read More
